On 18 May 2017, the FDA granted accelerated approval to pembrolizumab, a PD-1-targeting mAb, for use in patients with bladder cancer who have either received platinum-containing chemotherapy or who are cisplatin-ineligible [39]. The gene discussed is PDCD1; the disease is urinary bladder carcinoma.